title: Metformin suppresses interleukin (IL)-1beta-induced IL-8 production, aromatase activation, and proliferation of endometriotic stromal cells.
abstract: BACKGROUND
  Metformin, a widely used treatment for diabetes that improves insulin sensitivity, also has both antiinflammatory properties and a modulatory effect on ovarian steroid production, two actions that have been suggested to be efficacious in therapy for endometriosis.
  
  
  OBJECTIVE
  To determine whether metformin may be effective for the treatment of endometriosis, we evaluated the effects of this agent on inflammatory response, estradiol production, and proliferation of endometriotic stromal cells (ESCs).
  
  
  METHODS
  ESCs derived from ovarian endometriomas were cultured with various concentrations of metformin.
  
  
  METHODS
  IL-8 production, mRNA expression and aromatase activity, and 5-bromo-2'-deoxyuridine incorporation in ESCs were measured.
  
  
  RESULTS
  Metformin dose-dependently suppressed IL-1beta-induced IL-8 production, cAMP-induced mRNA expression and aromatase activity, and 5-bromo-2'-deoxyuridine incorporation in ESCs.
  
  
  CONCLUSIONS
  These results suggest that further investigation into the unique therapeutic potential of metformin as an antiendometriotic drug is warranted.
authors.affiliation: Department of Obstetrics and Gynecology, Faculty of Medicine, University of Tokyo, 7-3-1, Hongo, Bunkyo-ku, Tokyo 113-8655, Japan.
authors.forename: Yuri
authors.initials: Y
authors.lastname: Takemura
authors.forename: Yutaka
authors.initials: Y
authors.lastname: Osuga
authors.forename: Osamu
authors.initials: O
authors.lastname: Yoshino
authors.forename: Akiko
authors.initials: A
authors.lastname: Hasegawa
authors.forename: Tetsuya
authors.initials: T
authors.lastname: Hirata
authors.forename: Yasushi
authors.initials: Y
authors.lastname: Hirota
authors.forename: Emi
authors.initials: E
authors.lastname: Nose
authors.forename: Chieko
authors.initials: C
authors.lastname: Morimoto
authors.forename: Miyuki
authors.initials: M
authors.lastname: Harada
authors.forename: Kaori
authors.initials: K
authors.lastname: Koga
authors.forename: Toshiki
authors.initials: T
authors.lastname: Tajima
authors.forename: Tetsu
authors.initials: T
authors.lastname: Yano
authors.forename: Yuji
authors.initials: Y
authors.lastname: Taketani
mesh_terms: D000328:Adult; D000963:Antimetabolites; D001141:Aromatase / Q000378:metabolism*; D015415:Biomarkers; D001973:Bromodeoxyuridine; D002469:Cell Separation; D002470:Cell Survival / Q000187:drug effects; D002478:Cells, Cultured; D004715:Endometriosis / Q000473:pathology; D004717:Endometrium / Q000166:cytology / Q000187:drug effects / Q000378:metabolism*; D004789:Enzyme Activation / Q000187:drug effects; D004967:Estrogens / Q000502:physiology; D005260:Female; D006801:Humans; D007004:Hypoglycemic Agents / Q000494:pharmacology*; D007249:Inflammation / Q000378:metabolism / Q000473:pathology; D053583:Interleukin-1beta / Q000037:antagonists & inhibitors* / Q000494:pharmacology*; D016209:Interleukin-8 / Q000096:biosynthesis*; D007770:L-Lactate Dehydrogenase / Q000378:metabolism; D008687:Metformin / Q000494:pharmacology*; D008875:Middle Aged; D012333:RNA, Messenger / Q000096:biosynthesis; D020133:Reverse Transcriptase Polymerase Chain Reaction; D017154:Stromal Cells / Q000187:drug effects / Q000378:metabolism*
chemical_list: D000963:Antimetabolites; D015415:Biomarkers; D004967:Estrogens; D007004:Hypoglycemic Agents; D053583:Interleukin-1beta; D016209:Interleukin-8; D012333:RNA, Messenger; D008687:Metformin; D007770:L-Lactate Dehydrogenase; D001141:Aromatase; D001973:Bromodeoxyuridine